-
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Adding dynaCERT to Your CleanTech Portfolio
After spending 16 years and over $60 million to develop its CleanTech technology, dynaCERT Inc. (TSX: DYA |…
-
Hemostemix steps into the new year with capital and its critical clinical study data in hand
With a new management team spearheading Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), the Company started 2021 with…
